AU Patent

AU2019230014A1 — Aripiprazole dosing strategy

Assigned to Alkermes Pharma Ireland Ltd · Expires 2020-09-17 · 6y expired

What this patent protects

The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.

USPTO Abstract

The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019230014A1
Jurisdiction
AU
Classification
—
Expires
2020-09-17
Drug substance claim
No
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.